Prediction of the Response to Neoadjuvant Radiation Chemotherapy Through Texture Analysis Derived From Medical Imaging
NCT ID: NCT04920435
Last Updated: 2021-12-07
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
124 participants
OBSERVATIONAL
2019-01-02
2019-12-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Radiomics features provide complementary information about tumor heterogenity.
The aim of the investigators is to develop a model combining clinical and radiomic criteria able to predict complete pathological response.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Prediction of Response to Neoadjuvant Therapy in Rectal Cancer
NCT02439086
Assessment of Response Before, During and After Neoadjuvant Chemoradiotherapy in Rectal Cancer Patients
NCT01171300
Application of Multimodal MRI in Histological Grading and Prognostic Assessment of Rectal Cancer
NCT07269912
Predicting Pathological Complete Response of Rectal Cancer With Magnetic Resonance(MR) Radiomics
NCT03238885
Radiomics in Rectal Cancer
NCT05331040
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
COHORT
RETROSPECTIVE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
training population
patients from which we will develop the prediction model
No interventions assigned to this group
testing population
patients on whom we will test the prediction model
No interventions assigned to this group
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* patients who received concomitant radio-chemotherapy followed by surgery
* pre-therapeutic MRI and CT-scan dicom available
Exclusion Criteria
* lack of MRI or CT-scan
18 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
University Hospital, Brest
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Centre Hospitalier de Cornouaille
Quimper, Brittany Region, France
ICO
Nantes, Saint Herblain, France
CHRU de Brest (Morvan)
Brest, , France
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
RECTOMICS (29BRC20.0027)
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.